Navigation Links
Profound Medical Receives IDE Approval from FDA to Conduct TULSA Clinical Trial for New Treatment for Localized Prostate Cancer
Date:9/17/2013

Toronto, Ontario (PRWEB) September 17, 2013

Profound Medical Inc. today announced that the US Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to the company to conduct a clinical study of its device for the treatment of localized prostate cancer. The company is now proceeding with U.S. institutional review board submissions and anticipates initiating patient enrollment later this year.

"This is another exciting milestone for Profound Medical and we look forward to initiating our U.S. clinical trial in the coming months. The TULSA trial is a key step in validating a new, alternative therapy for treating localized prostate cancer that minimizes the risks commonly associated with treatment," states Steven Plymale, CEO at Profound Medical.

The Profound device presents the potential for significantly improved clinical outcomes and represents a marked departure from current methods by virtue of its ability to treat the whole gland in one session, with unprecedented accuracy and minimal side effects. "The objective of the TULSA trial is to demonstrate that effective elimination of cancerous tissue can be achieved safely, precisely and with significantly less risk to bladder, bowel, and erectile functions," comments Plymale.

Combining the use of thermal ultrasound therapy with real-time MR Image guidance, the Profound system operates safely within an MRI suite, offering unparalleled accuracy, using a minimally invasive, trans-urethral approach. Performed as a single session outpatient procedure, the Profound treatment affords the patient the ability to return home after a short recovery period.

Leveraging years of research and development, initiated in collaboration with the Sunnybrook Research Institute, Profound Medical’s technology is currently at clinical-ready stage. The device can function across multiple MRI platforms from various vendors and can be moved independently from scanner to scanner. Profound Medical’s TULSA trial will effectively collect clinical data in multiple jurisdictions concurrently, accelerating the company’s commercialization plans. "We believe the TULSA clinical trial will radically change the perception of localized prostate cancer treatment, raising the bar for improved efficacy, faster recovery, and better long-term quality of life" concludes Plymale.

About Profound Medical Inc

PMI is a Canadian medical device company that is developing and commercializing a unique, minimally invasive treatment for prostate cancer. PMI’s novel technology combines Magnetic Resonance Imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland. Delivered via a trans-urethral approach, the technique combines the image quality of MRI with thermal ultrasound as the treatment tool. This method of prostate cancer treatment affords highly accurate and precise treatment within the prostate gland in a short time span in an outpatient setting. The potential of this technology is currently being demonstrated in Phase I clinical trials.

For more information, please contact:

Steven Plymale Tel: +1 647 476 1350 ext. 401 Fax: +1 647 847 3739

Read the full story at http://www.prweb.com/releases/prostate/cancer/prweb11125102.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
2. DiaTech Life Sciences Announces Medical Advisory Board
3. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
4. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
5. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
6. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
7. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
8. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
9. Live Press Briefing on Findings of Biomedical Industry CEO Survey
10. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
11. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. announced ... presenting at the Annual Biocom Global Life Science Partnering ... at 11:15 AM, at the Torrey Pines Lodge, in ... the organizers at Biocom who have chosen our company, ... of biotechnology companies, investors, and clinical researchers," said Mr. ...
(Date:2/22/2017)... ... 22, 2017 , ... LabRoots , the leading provider of educational and ... pleased to announce the launch of a new scholarship for young scientists seeking a ... merit-based scholarship is open to all high school seniors, 17 years or older; as ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech consulting firm ... director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings 14 ... more than a decade with leading market research firm, GfK. He began his ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, CloudMine, ... applications, announced a partnership with Redox, a leader in cloud-based healthcare integration and ... systems while keeping data secure in the cloud. , The digital health developers, ...
Breaking Biology Technology:
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):